AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18849052 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group for children aged 6 to 48 months)
Number of subjects: 243
Study 18849052 — intervention group
Group type: COMPARATOR
Intervention: No breast-feeding (control group for infants under 6 months)
Number of subjects: 243
Study 18849052 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose vs. Lidocaine-prilocaine (for children aged 6 to 48 months)
Number of subjects: 243
Study 16786183 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contact tonometry (Reichert AT550)
Number of subjects: 55
Study 16786183 — intervention group
Group type: COMPARATOR
Intervention: Applanation tonometry (Goldman)
Number of subjects: 55
Study 15131545 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin alone (to reduce LDL cholesterol to < or =80 mg/dL)
Number of subjects: 300
Study 15131545 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin plus antioxidant vitamins C and E (to reduce LDL cholesterol to < or =80 mg/dL)
Number of subjects: 300
Study 15131545 — intervention group
Group type: COMPARATOR
Intervention: Control (diet and low-dose lovastatin to reduce LDL cholesterol to < or =130 mg/dL)
Number of subjects: 300
Study 11315836 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 23
Study 9040271 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical therapy (twice a week for 60 minutes with a therapist, daily unsupervised exercise for 15 minutes)
Number of subjects: 24
Study 9040271 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical therapy
Number of subjects: 24
Study 9040271 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 24
Study 8187304 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (Humatrope, Eli Lilly) 0.5 U/kg/week
Number of subjects: 10
Study 8187304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3116238 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I received a nutrient solution providing 10 grams of nitrogen as Perifusin and 1400 calories as dextrose and Intralipid with an osmolality of 490 mosmol/kg
Number of subjects: 20
Study 3116238 — intervention group
Group type: COMPARATOR
Intervention: Group II received only 15 grams of nitrogen per day as Perifusin with an osmolality of 376 mosmol/kg
Number of subjects: 20
Study 3116238 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 20
Study 3116238 — intervention group
Group type: COMPARATOR
Intervention: Group II
Number of subjects: 20
Study 3116238 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 30907987 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (50 μg once daily)
Number of subjects: 952
Study 28077730 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of measles vaccine (MV) at 18 weeks and 9 months
Number of subjects: 1592
Study 28077730 — intervention group
Group type: COMPARATOR
Intervention: 1 dose of measles vaccine (MV) at age 9 months
Number of subjects: 1592
Study 26055400 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60
Study 26055400 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 23419384 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy (GHT) with supportive talks and medical treatment (SMT)
Number of subjects: 100
Study 23419384 — intervention group
Group type: COMPARATOR
Intervention: Supportive talks with medical treatment (SMT)
Number of subjects: 100
Study 23419384 — intervention group
Group type: EXPERIMENTAL
Intervention: GHT with SMT
Number of subjects: 100
Study 21393467 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-programmed response
Number of subjects: 7
Study 21393467 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct optimization
Number of subjects: 7
Study 19274363 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO Child Growth Standards
Number of subjects: 806
Study 19274363 — intervention group
Group type: COMPARATOR
Intervention: IAP growth curves
Number of subjects: 806
Study 17867402 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel infant tooth wipe (Spiffies)
Number of subjects: 35
Study 17867402 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (Ultra Kids)
Number of subjects: 35
Study 14758818 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (809 nm‐GaAlAs‐laser, 50 mW, 150 s)
Number of subjects: 52
Study 14758818 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (simulated laser treatment)
Number of subjects: 52
Study 11355044 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) with conjugated estrogens (0.625 mg/day) and medroxyprogesterone (2.5 mg/day) for 12 months
Number of subjects: 70
Study 11355044 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HRT)
Number of subjects: 70
Study 9207871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen-arginine (400 mg orally, 90 min before surgery, 2 h after surgery, then every 8 h for 32 hours)
Number of subjects: 30
Study 9207871 — intervention group
Group type: COMPARATOR
Intervention: Placebo (doubled blind, same timing as ibuprofen-arginine)
Number of subjects: 30
Study 9207871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen-arginine
Number of subjects: 30
Study 9207871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9207871 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen-arginine and Placebo
Number of subjects: 30
Study 7953427 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 per cent glyceryl trinitrate ointment
Number of subjects: 30
Study 7953427 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 30
Study 3591249 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/kg of 0.5% bupivacaine injected for the block (Group 1)
Number of subjects: 40
Study 3591249 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine 0.25 mg/kg/h infusion (Group 2)
Number of subjects: 40
Study 3591249 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/kg of 0.5% bupivacaine (Group 1)
Number of subjects: 40
Study 3591249 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plasma concentration (Group 1)
Number of subjects: 40
Study 3591249 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine plasma concentration (Group 2)
Number of subjects: 40
Study 3591249 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plasma levels (Group 1)
Number of subjects: 40
Study 3591249 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine plasma levels (Group 2)
Number of subjects: 40
Study 3591249 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic effects
Number of subjects: 40
Study 28287913 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill-based bibliotherapy intervention
Number of subjects: 45
Study 28287913 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill intervention
Number of subjects: 45
Study 26915375 — intervention group
Group type: EXPERIMENTAL
Intervention: Late Sodium Current Inhibition
Number of subjects: 0
Study 26915375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24233772 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard triple anti‐H. pylori therapy plus probiotics of L. acidophilus and B. bifidum for 2 weeks followed by taking probiotics for another 4 weeks
Number of subjects: 100
Study 24233772 — intervention group
Group type: COMPARATOR
Intervention: Standard triple anti‐H. pylori therapy for 6 weeks
Number of subjects: 100
Study 24233772 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard triple anti‐H. pylori therapy plus probiotics of L. acidophilus and B. bifidum
Number of subjects: 100
Study 23285445 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nitrate cautery
Number of subjects: 94
Study 23285445 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 94
Study 20339787 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical heparin treatment (group TH)
Number of subjects: 58
Study 20339787 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (group C)
Number of subjects: 58
Study 17899018 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oxycodone
Number of subjects: 20
Study 17899018 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oxycodone
Number of subjects: 20
Study 17899018 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg morphine
Number of subjects: 20
Study 17899018 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg morphine
Number of subjects: 20
Study 17899018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16087981 — intervention group
Group type: EXPERIMENTAL
Intervention: Valine intake of 17 mg x kg(‐1) x d(‐1)
Number of subjects: 18
Study 16087981 — intervention group
Group type: EXPERIMENTAL
Intervention: Valine intakes of 5, 10, 15, 20, 25, 30, and 35 mg x kg(‐1) x d(‐1)
Number of subjects: 18
Study 16087981 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine intake maintained at 40 mg x kg(‐1) x d(‐1)
Number of subjects: 18
Study 12098023 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted camera control (RACC) using the AESOP 2000 system
Number of subjects: 20
Study 12098023 — intervention group
Group type: COMPARATOR
Intervention: Human camera control
Number of subjects: 20
Study 12098023 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted camera control (RACC)
Number of subjects: 20
Study 10332195 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of adriamycin (ADM) + vincristine (VCR) + cyclophosphamide (CPM) + mitoxantrone + L-asparaginase
Number of subjects: 20
Study 10332195 — intervention group
Group type: EXPERIMENTAL
Intervention: ADM + VCR + PSL
Number of subjects: 20
Study 10332195 — intervention group
Group type: EXPERIMENTAL
Intervention: VCR + PSL
Number of subjects: 20
Study 10332195 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuated induction therapy for patients aged 75 or over
Number of subjects: 20
Study 10332195 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard induction therapy for patients aged less than 75
Number of subjects: 20
Study 10332195 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 20
Study 8942334 — intervention group
Group type: COMPARATOR
Intervention: Saline (5 ml)
Number of subjects: 0
Study 8942334 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium (0.75 mg kg‐1)
Number of subjects: 0
Study 8942334 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (0.24 mg kg‐1)
Number of subjects: 0
Study 8942334 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (0.05 mg kg‐1)
Number of subjects: 0
Study 1574284 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1%
Number of subjects: 92
Study 1574284 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle only)
Number of subjects: 92
Study 3936186 — intervention group
Group type: EXPERIMENTAL
Intervention: Generous insurance plans
Number of subjects: 0
Study 3936186 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-sharing for drugs
Number of subjects: 0
Study 3936186 — intervention group
Group type: EXPERIMENTAL
Intervention: Dayton, Ohio site
Number of subjects: 0
Study 3936186 — intervention group
Group type: COMPARATOR
Intervention: Insurance plan
Number of subjects: 0
Study 31244668 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR resistance training (30‐40% 1RM unilateral knee extension) for 8 weeks
Number of subjects: 24
Study 31244668 — intervention group
Group type: COMPARATOR
Intervention: Usual exercise routine
Number of subjects: 24
Study 28724636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab therapy
Number of subjects: 0
Study 28724636 — intervention group
Group type: COMPARATOR
Intervention: Laser therapy
Number of subjects: 0
Study 25222757 — intervention group
Group type: EXPERIMENTAL
Intervention: High insulin with essential amino acids (EAAs)
Number of subjects: 30
Study 25222757 — intervention group
Group type: COMPARATOR
Intervention: Low insulin with EAAs
Number of subjects: 30
Study 25222757 — intervention group
Group type: COMPARATOR
Intervention: Low insulin
Number of subjects: 30
Study 25222757 — intervention group
Group type: COMPARATOR
Intervention: High insulin
Number of subjects: 30
Study 25222757 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA infusion
Number of subjects: 30
Study 23229963 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus on Medicines (FOM) program
Number of subjects: 128
Study 21149757 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine taken at bedtime
Number of subjects: 105
Study 17662105 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (T) - 6-month, part-time, mixed-methods training course provided by the Royal College of General Practitioners
Number of subjects: 112
Study 17662105 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (WL)
Number of subjects: 112
Study 17662105 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (T)
Number of subjects: 112
Study 15857930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) therapy, administered as three monthly infusions.
Number of subjects: 0
Study 15857930 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group of sIBM patients who did not improve).
Number of subjects: 0
Study 11986599 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MVR (complete chordal preservation)
Number of subjects: 36
Study 11986599 — intervention group
Group type: COMPARATOR
Intervention: P-MVR (partial chordal preservation)
Number of subjects: 36
Study 11490530 — intervention group
Group type: EXPERIMENTAL
Intervention: 32P alone
Number of subjects: 483
Study 11490530 — intervention group
Group type: EXPERIMENTAL
Intervention: 32P followed by low-dose hydroxyurea (HU) maintenance therapy
Number of subjects: 483
Study 8017870 — intervention group
Group type: COMPARATOR
Intervention: 4-aminopyridine (AP), oral treatment for 3 months
Number of subjects: 68
Study 8017870 — intervention group
Group type: COMPARATOR
Intervention: 3,4 diaminopyridine (DAP), open-label trial
Number of subjects: 68
Study 8017870 — intervention group
Group type: COMPARATOR
Intervention: 3,4 diaminopyridine (DAP), double-blind placebo-controlled trial
Number of subjects: 68
Study 8017870 — intervention group
Group type: COMPARATOR
Intervention: Crossover comparison of AP and DAP
Number of subjects: 68
Study 2849011 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (7 ng/kg/min)
Number of subjects: 3
Study 2849011 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (1 ng/kg/min)
Number of subjects: 3
Study 2849011 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (1 ng/kg/min)
Number of subjects: 3
Study 2849011 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Angiotensin II and Vasopressin with CRF41 (100 micrograms)
Number of subjects: 3
Study 2849011 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin with CRF41 (100 micrograms)
Number of subjects: 3
Study 31742782 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage mite sensitization
Number of subjects: 1180
Study 31742782 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite (HDM) sensitization
Number of subjects: 1180
Study 31742782 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-sensitization to HDM among storage mite sensitized individuals
Number of subjects: 1180
Study 31742782 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory symptoms and asthma
Number of subjects: 1180
Study 31742782 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors (age, education, pet keeping, place of upbringing)
Number of subjects: 1180
Study 29439943 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia (IM) group
Number of subjects: 60
Study 29439943 — intervention group
Group type: COMPARATOR
Intervention: Conventional Microsoft PowerPoint show (PPS) group
Number of subjects: 60
Study 27825724 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation techniques
Number of subjects: 180
Study 27825724 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery rescripting
Number of subjects: 180
Study 27825724 — intervention group
Group type: COMPARATOR
Intervention: Moderated self-help group
Number of subjects: 180
Study 26529074 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered intradermal influenza vaccine (Intanza(®))
Number of subjects: 810
Study 26529074 — intervention group
Group type: COMPARATOR
Intervention: Nurse-administered intramuscular vaccine (Vaxigrip(®))
Number of subjects: 810
Study 26529074 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led group sessions for self-administration
Number of subjects: 810
Study 23789889 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented insulin-pump therapy with threshold-suspend feature
Number of subjects: 247
Study 23789889 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard sensor-augmented insulin-pump therapy)
Number of subjects: 247
Study 21552138 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri 1×10 colony-forming units twice daily for 4 weeks
Number of subjects: 31
Study 21552138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 18513270 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric variable stiffness colonoscope (PVSC)
Number of subjects: 216
Study 18513270 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmagnifying adult variable stiffness colonoscope (AVSC)
Number of subjects: 216
Study 18513270 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnifying variable stiffness colonoscope (MVSC)
Number of subjects: 216
Study 17151157 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 39
Study 17151157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 15457336 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulation device
Number of subjects: 6
Study 15457336 — intervention group
Group type: COMPARATOR
Intervention: Prior reports on rhythmic auditory facilitation
Number of subjects: 6
Study 10933353 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus 20 mg/day simvastatin
Number of subjects: 16
Study 10933353 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 16
Study 8825266 — intervention group
Group type: EXPERIMENTAL
Intervention: Madopar HBS
Number of subjects: 134
Study 8825266 — intervention group
Group type: COMPARATOR
Intervention: Standard Madopar
Number of subjects: 134
Study 1317048 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exposure to alcohol
Number of subjects: 0
Study 1317048 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exposure to cocaine
Number of subjects: 0
Study 1317048 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal from alcohol
Number of subjects: 0
Study 1317048 — intervention group
Group type: COMPARATOR
Intervention: Thyroid and prolactin regulation measures
Number of subjects: 0
Study 1317048 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed index of HPA axis dysfunction
Number of subjects: 0
Study 3956105 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathlessness scaling using visual analogue scaling
Number of subjects: 0
Study 3956105 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitude estimation of breathlessness
Number of subjects: 0
Study 29304734 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-notification postcard
Number of subjects: 28134
Study 29304734 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer questionnaire
Number of subjects: 28134
Study 29304734 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder
Number of subjects: 28134
Study 27271809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 1 (high levels of overall QOL)
Number of subjects: 0
Study 27271809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 2 (medium levels of overall QOL)
Number of subjects: 0
Study 27271809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 3 (medium levels of overall QOL)
Number of subjects: 0
Study 27271809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 4 (low levels of overall QOL)
Number of subjects: 0
Study 25047308 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic surgery (SIL-V)
Number of subjects: 69
Study 25047308 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic varicocelectomy (CL-V)
Number of subjects: 69
Study 22989894 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone questionnaire
Number of subjects: 120
Study 22989894 — intervention group
Group type: COMPARATOR
Intervention: Pen-and-paper questionnaire
Number of subjects: 120
Study 20120420 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment
Number of subjects: 100
Study 18407355 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% alcoholic chlorhexidine
Number of subjects: 2146
Study 18407355 — intervention group
Group type: COMPARATOR
Intervention: 10% aqueous povidone-iodine
Number of subjects: 2146
Study 15653255 — intervention group
Group type: EXPERIMENTAL
Intervention: FAQ checklist mailed to patients after 1, 4, and 10 months post-discharge for CAD.
Number of subjects: 105
Study 15653255 — intervention group
Group type: COMPARATOR
Intervention: Control group (no checklist).
Number of subjects: 105
Study 11831346 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive jaw motion device therapy (Therabite)
Number of subjects: 43
Study 11831346 — intervention group
Group type: EXPERIMENTAL
Intervention: Wooden tongue depressors therapy (WTD)
Number of subjects: 43
Study 11831346 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 10362007 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (n = 23), combined endurance and strength training at 75% to 80% intensity, 3 times/week for 6 months.
Number of subjects: 49
Study 10362007 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 26), nonexercise.
Number of subjects: 49
Study 7741566 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler (MDI) with a valved holding chamber
Number of subjects: 111
Study 7741566 — intervention group
Group type: COMPARATOR
Intervention: Nebuliser driven by air
Number of subjects: 111
Study 2048819 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide, 800 micrograms twice a day
Number of subjects: 40